Dr. Facciabene on the Potential Benefit of Gut Microbiota Tuning in Lymphoma

Andrea Facciabene, PhD, discusses the potential benefit of gut microbiota tuning in lymphoma.

Andrea Facciabene, PhD, research associate professor of radiation oncology, Department of Radiation Oncology, University of Pennsylvania Perelman School of Medicine, Penn Medicine, discusses the potential benefit of gut microbiota tuning in lymphoma. 

Observations in murine models and human ALL and non-Hodgkin lymphoma patients, presented during the 2021 ASH Annual Meeting and Exposition suggest that the gut microbiota influence the outcome of CART therapy and that a titrated modulation by antibiotics or probiotics/fecal transfer approaches could increase the clinical benefit for patients treated with CART therapy, Facciabene says.

It is anticipated that patients will benefit from this research; however, it is too early to make conclusions, Facciabene explains. Despite this, the research could also lead to a novel approach for the identification of a microbiome signature that would determine which patients are more likely to respond to CART therapy, Facciabene says.

Overall, progress has been made in what has been tested thus far with lymphoma-bearing mice and in human patients with NHL and ALL, Facciabene continues. However, the data support the extension of our studies in translational research into human clinical trials, Facciabene concludes.